| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 310 | 2024 | 5317 | 23.700 |
Why?
|
| Skin Neoplasms | 168 | 2024 | 4654 | 14.780 |
Why?
|
| Interferon-alpha | 64 | 2022 | 889 | 10.100 |
Why?
|
| Cancer Vaccines | 34 | 2021 | 697 | 5.370 |
Why?
|
| Adjuvants, Immunologic | 21 | 2024 | 657 | 3.500 |
Why?
|
| Ipilimumab | 28 | 2024 | 710 | 3.440 |
Why?
|
| Proto-Oncogene Proteins B-raf | 29 | 2023 | 1283 | 3.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 61 | 2024 | 15862 | 2.600 |
Why?
|
| Antineoplastic Agents | 61 | 2021 | 14289 | 2.380 |
Why?
|
| Immunotherapy | 43 | 2022 | 3341 | 2.200 |
Why?
|
| Chemotherapy, Adjuvant | 39 | 2023 | 3890 | 2.170 |
Why?
|
| Recombinant Proteins | 45 | 2018 | 2927 | 2.170 |
Why?
|
| Antigens, Neoplasm | 22 | 2021 | 1506 | 2.120 |
Why?
|
| Oximes | 12 | 2023 | 175 | 2.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 2017 | 408 | 2.010 |
Why?
|
| Antibodies, Monoclonal | 25 | 2018 | 4367 | 1.970 |
Why?
|
| Interferons | 10 | 2019 | 291 | 1.840 |
Why?
|
| Programmed Cell Death 1 Receptor | 21 | 2023 | 1048 | 1.750 |
Why?
|
| Humans | 341 | 2024 | 261506 | 1.740 |
Why?
|
| Neoplasm Staging | 72 | 2023 | 13658 | 1.690 |
Why?
|
| Biomarkers, Tumor | 33 | 2021 | 10331 | 1.660 |
Why?
|
| Interleukin-2 | 17 | 2022 | 842 | 1.630 |
Why?
|
| Dacarbazine | 19 | 2021 | 485 | 1.540 |
Why?
|
| Dendritic Cells | 12 | 2021 | 1085 | 1.460 |
Why?
|
| Vaccines, Subunit | 7 | 2017 | 124 | 1.460 |
Why?
|
| Pyridones | 10 | 2023 | 348 | 1.400 |
Why?
|
| Antineoplastic Agents, Immunological | 10 | 2023 | 1249 | 1.370 |
Why?
|
| Imidazoles | 11 | 2020 | 999 | 1.360 |
Why?
|
| Middle Aged | 134 | 2023 | 86204 | 1.300 |
Why?
|
| CTLA-4 Antigen | 15 | 2022 | 657 | 1.260 |
Why?
|
| Adult | 121 | 2023 | 77950 | 1.250 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2022 | 551 | 1.250 |
Why?
|
| Antigens, CD | 12 | 2022 | 1385 | 1.230 |
Why?
|
| Male | 156 | 2023 | 123000 | 1.220 |
Why?
|
| Pyrimidinones | 8 | 2020 | 314 | 1.220 |
Why?
|
| Aged | 121 | 2023 | 70117 | 1.210 |
Why?
|
| Disease-Free Survival | 42 | 2021 | 10001 | 1.200 |
Why?
|
| Prognosis | 58 | 2023 | 21713 | 1.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 9 | 2014 | 588 | 1.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 25 | 2024 | 3251 | 1.120 |
Why?
|
| Neoadjuvant Therapy | 12 | 2023 | 4975 | 1.110 |
Why?
|
| Female | 154 | 2023 | 141928 | 1.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 19 | 2022 | 1586 | 1.100 |
Why?
|
| Benzimidazoles | 4 | 2015 | 428 | 1.100 |
Why?
|
| Aged, 80 and over | 70 | 2021 | 29902 | 1.090 |
Why?
|
| Dasatinib | 2 | 2021 | 862 | 1.080 |
Why?
|
| Nevus | 3 | 2020 | 107 | 1.080 |
Why?
|
| Uveal Neoplasms | 6 | 2023 | 176 | 1.070 |
Why?
|
| Survival Analysis | 40 | 2021 | 9180 | 1.020 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2023 | 1555 | 1.020 |
Why?
|
| Nevus, Pigmented | 3 | 2020 | 104 | 1.000 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2018 | 355 | 1.000 |
Why?
|
| Sentinel Lymph Node Biopsy | 12 | 2020 | 1415 | 0.970 |
Why?
|
| Neoplasm Metastasis | 24 | 2020 | 5112 | 0.960 |
Why?
|
| Telomerase | 5 | 2022 | 525 | 0.920 |
Why?
|
| Clinical Trials as Topic | 23 | 2020 | 3719 | 0.920 |
Why?
|
| CD4-Positive T-Lymphocytes | 18 | 2021 | 1033 | 0.910 |
Why?
|
| Quinolines | 3 | 2021 | 383 | 0.900 |
Why?
|
| Receptor, Interferon alpha-beta | 4 | 2019 | 23 | 0.890 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2022 | 371 | 0.880 |
Why?
|
| Kaplan-Meier Estimate | 25 | 2020 | 6207 | 0.870 |
Why?
|
| Autophagosomes | 2 | 2021 | 38 | 0.850 |
Why?
|
| Treatment Outcome | 62 | 2021 | 32848 | 0.840 |
Why?
|
| Receptors, Death Domain | 1 | 2021 | 7 | 0.830 |
Why?
|
| Young Adult | 39 | 2022 | 21445 | 0.820 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 9 | 2022 | 992 | 0.810 |
Why?
|
| Protein Kinase Inhibitors | 13 | 2022 | 4757 | 0.800 |
Why?
|
| Lymphatic Metastasis | 19 | 2020 | 4844 | 0.790 |
Why?
|
| B7-H1 Antigen | 3 | 2019 | 1022 | 0.780 |
Why?
|
| Molecular Targeted Therapy | 13 | 2020 | 2330 | 0.770 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2021 | 4938 | 0.760 |
Why?
|
| Membrane Proteins | 15 | 2021 | 2819 | 0.750 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2017 | 673 | 0.750 |
Why?
|
| Double-Blind Method | 16 | 2023 | 2588 | 0.740 |
Why?
|
| Autoimmunity | 5 | 2014 | 263 | 0.720 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2022 | 192 | 0.710 |
Why?
|
| Toll-Like Receptor 9 | 3 | 2021 | 78 | 0.710 |
Why?
|
| GTP Phosphohydrolases | 4 | 2018 | 336 | 0.710 |
Why?
|
| Immunologic Factors | 7 | 2019 | 649 | 0.710 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 1375 | 0.710 |
Why?
|
| Peptide Fragments | 9 | 2015 | 1271 | 0.700 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2022 | 26 | 0.700 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 615 | 0.690 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2021 | 598 | 0.690 |
Why?
|
| Mutation | 23 | 2023 | 15179 | 0.690 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2020 | 388 | 0.680 |
Why?
|
| Epitopes, T-Lymphocyte | 10 | 2010 | 219 | 0.680 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2024 | 2594 | 0.670 |
Why?
|
| Drug Administration Schedule | 16 | 2018 | 3472 | 0.670 |
Why?
|
| Brassica | 1 | 2018 | 19 | 0.650 |
Why?
|
| Sentinel Lymph Node | 2 | 2017 | 216 | 0.640 |
Why?
|
| Isothiocyanates | 1 | 2018 | 44 | 0.640 |
Why?
|
| Drug Resistance, Neoplasm | 16 | 2021 | 5178 | 0.630 |
Why?
|
| Combined Modality Therapy | 17 | 2024 | 8865 | 0.630 |
Why?
|
| Practice Guidelines as Topic | 6 | 2021 | 2403 | 0.620 |
Why?
|
| Anticarcinogenic Agents | 1 | 2020 | 362 | 0.620 |
Why?
|
| Quality of Life | 6 | 2023 | 4532 | 0.610 |
Why?
|
| Nurse's Role | 1 | 2017 | 42 | 0.600 |
Why?
|
| Neoplasms | 18 | 2023 | 15193 | 0.600 |
Why?
|
| Autoantibodies | 3 | 2014 | 576 | 0.600 |
Why?
|
| STAT3 Transcription Factor | 4 | 2008 | 1121 | 0.590 |
Why?
|
| Lymphocyte Activation | 12 | 2021 | 1688 | 0.590 |
Why?
|
| Reactive Oxygen Species | 2 | 2021 | 987 | 0.590 |
Why?
|
| Meta-Analysis as Topic | 5 | 2020 | 276 | 0.580 |
Why?
|
| Freund's Adjuvant | 5 | 2017 | 43 | 0.580 |
Why?
|
| HLA-A2 Antigen | 2 | 2015 | 159 | 0.580 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2015 | 460 | 0.560 |
Why?
|
| Oligodeoxyribonucleotides | 4 | 2013 | 261 | 0.550 |
Why?
|
| Early Detection of Cancer | 5 | 2022 | 1258 | 0.550 |
Why?
|
| Brain Neoplasms | 15 | 2023 | 4849 | 0.550 |
Why?
|
| Plant Extracts | 1 | 2018 | 215 | 0.550 |
Why?
|
| Vaginal Neoplasms | 1 | 2017 | 152 | 0.540 |
Why?
|
| Tumor Microenvironment | 13 | 2023 | 2864 | 0.540 |
Why?
|
| Adolescent | 31 | 2022 | 31252 | 0.540 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 4549 | 0.530 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 313 | 0.530 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 98 | 0.510 |
Why?
|
| Vulvar Neoplasms | 1 | 2017 | 236 | 0.510 |
Why?
|
| Community Health Services | 1 | 2016 | 126 | 0.510 |
Why?
|
| Interleukin-18 | 3 | 2011 | 100 | 0.500 |
Why?
|
| Follow-Up Studies | 26 | 2020 | 14889 | 0.490 |
Why?
|
| Disease Progression | 18 | 2023 | 6682 | 0.490 |
Why?
|
| Sulfonamides | 7 | 2017 | 1823 | 0.480 |
Why?
|
| Gene Expression Regulation, Neoplastic | 17 | 2022 | 8873 | 0.480 |
Why?
|
| Monitoring, Immunologic | 1 | 2014 | 47 | 0.480 |
Why?
|
| Oncolytic Virotherapy | 3 | 2023 | 280 | 0.480 |
Why?
|
| MAP Kinase Signaling System | 4 | 2020 | 848 | 0.480 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2017 | 1248 | 0.480 |
Why?
|
| Gene Expression Profiling | 13 | 2023 | 5159 | 0.480 |
Why?
|
| Survival Rate | 26 | 2020 | 12221 | 0.470 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2014 | 95 | 0.470 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 66 | 0.470 |
Why?
|
| BCG Vaccine | 3 | 2008 | 399 | 0.470 |
Why?
|
| Th1 Cells | 4 | 2019 | 250 | 0.460 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 3 | 2018 | 36 | 0.460 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2013 | 223 | 0.450 |
Why?
|
| Radiosurgery | 8 | 2017 | 1330 | 0.450 |
Why?
|
| Cell Line, Tumor | 25 | 2022 | 14551 | 0.440 |
Why?
|
| Cell Proliferation | 9 | 2020 | 7226 | 0.430 |
Why?
|
| Time Factors | 23 | 2021 | 12926 | 0.430 |
Why?
|
| Proportional Hazards Models | 12 | 2019 | 4988 | 0.430 |
Why?
|
| Lymphocyte Subsets | 2 | 2010 | 137 | 0.430 |
Why?
|
| Signal Transduction | 18 | 2021 | 11965 | 0.420 |
Why?
|
| Biostatistics | 1 | 2011 | 20 | 0.410 |
Why?
|
| Chemistry, Clinical | 1 | 2011 | 18 | 0.410 |
Why?
|
| Interferon-gamma | 11 | 2020 | 1144 | 0.410 |
Why?
|
| HLA-DR Antigens | 5 | 2007 | 173 | 0.400 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2011 | 104 | 0.400 |
Why?
|
| Quinolones | 2 | 2012 | 160 | 0.400 |
Why?
|
| Benzamides | 3 | 2018 | 1832 | 0.400 |
Why?
|
| Risk Factors | 16 | 2023 | 17523 | 0.390 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2011 | 153 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 1303 | 0.390 |
Why?
|
| STAT1 Transcription Factor | 4 | 2011 | 156 | 0.390 |
Why?
|
| Killer Cells, Natural | 5 | 2020 | 904 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2023 | 10035 | 0.380 |
Why?
|
| Thionucleotides | 2 | 2007 | 65 | 0.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2017 | 665 | 0.370 |
Why?
|
| Risk Assessment | 13 | 2023 | 6869 | 0.370 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 527 | 0.370 |
Why?
|
| Consensus | 8 | 2020 | 978 | 0.370 |
Why?
|
| Peptides | 4 | 2013 | 1479 | 0.370 |
Why?
|
| Forkhead Transcription Factors | 5 | 2017 | 778 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2018 | 1533 | 0.360 |
Why?
|
| Lymph Nodes | 8 | 2017 | 2967 | 0.360 |
Why?
|
| Neoplasm Proteins | 11 | 2019 | 3230 | 0.350 |
Why?
|
| Skin | 3 | 2020 | 1259 | 0.350 |
Why?
|
| Drug Discovery | 1 | 2011 | 324 | 0.330 |
Why?
|
| Case-Control Studies | 7 | 2022 | 6100 | 0.330 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2022 | 5437 | 0.330 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 109 | 0.320 |
Why?
|
| Dermatologic Surgical Procedures | 3 | 2019 | 106 | 0.320 |
Why?
|
| Biomarkers | 7 | 2023 | 5047 | 0.320 |
Why?
|
| S100 Proteins | 1 | 2008 | 181 | 0.320 |
Why?
|
| Extracellular Vesicles | 2 | 2021 | 135 | 0.310 |
Why?
|
| STAT5 Transcription Factor | 1 | 2008 | 214 | 0.310 |
Why?
|
| Interferon Type I | 2 | 2016 | 250 | 0.310 |
Why?
|
| Niacinamide | 6 | 2015 | 421 | 0.310 |
Why?
|
| Exosomes | 2 | 2021 | 253 | 0.300 |
Why?
|
| Drug Synergism | 6 | 2021 | 1313 | 0.300 |
Why?
|
| Immunohistochemistry | 11 | 2020 | 7548 | 0.290 |
Why?
|
| Interleukin-17 | 1 | 2008 | 250 | 0.290 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2007 | 248 | 0.290 |
Why?
|
| Transcriptome | 5 | 2023 | 1859 | 0.290 |
Why?
|
| Melanocytes | 4 | 2016 | 219 | 0.290 |
Why?
|
| Antigens, Differentiation | 1 | 2007 | 238 | 0.290 |
Why?
|
| Animals | 28 | 2020 | 59536 | 0.280 |
Why?
|
| Vaccination | 5 | 2020 | 1123 | 0.280 |
Why?
|
| Sunbathing | 2 | 2020 | 10 | 0.280 |
Why?
|
| Cytokines | 6 | 2023 | 2809 | 0.280 |
Why?
|
| Biomedical Research | 5 | 2021 | 806 | 0.280 |
Why?
|
| Integrins | 1 | 2007 | 262 | 0.270 |
Why?
|
| Choroid Neoplasms | 4 | 2008 | 41 | 0.270 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2013 | 1016 | 0.270 |
Why?
|
| Phenylurea Compounds | 6 | 2015 | 580 | 0.270 |
Why?
|
| Prospective Studies | 10 | 2022 | 12873 | 0.270 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2020 | 299 | 0.270 |
Why?
|
| Isotretinoin | 1 | 2005 | 158 | 0.260 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 5767 | 0.260 |
Why?
|
| Carboplatin | 5 | 2015 | 823 | 0.260 |
Why?
|
| Smallpox Vaccine | 1 | 2005 | 43 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 4 | 2022 | 3101 | 0.260 |
Why?
|
| Receptors, Immunologic | 2 | 2020 | 309 | 0.250 |
Why?
|
| Indoles | 5 | 2014 | 1009 | 0.250 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 703 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2016 | 2326 | 0.250 |
Why?
|
| Immunodominant Epitopes | 4 | 2010 | 61 | 0.250 |
Why?
|
| Immune Tolerance | 3 | 2020 | 403 | 0.250 |
Why?
|
| Polyvinyls | 1 | 2004 | 19 | 0.250 |
Why?
|
| Patient Selection | 5 | 2020 | 2055 | 0.240 |
Why?
|
| Apoptosis | 6 | 2014 | 7591 | 0.240 |
Why?
|
| Biopsy | 4 | 2018 | 3443 | 0.240 |
Why?
|
| Retrospective Studies | 19 | 2022 | 37905 | 0.240 |
Why?
|
| Tumor Escape | 3 | 2015 | 251 | 0.230 |
Why?
|
| Cisplatin | 5 | 2017 | 2432 | 0.230 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 1021 | 0.230 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2018 | 1331 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 2 | 2007 | 1547 | 0.230 |
Why?
|
| Registries | 3 | 2023 | 2170 | 0.220 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2004 | 181 | 0.220 |
Why?
|
| Telomere Homeostasis | 1 | 2022 | 73 | 0.210 |
Why?
|
| Pilot Projects | 4 | 2021 | 2803 | 0.210 |
Why?
|
| Telomere-Binding Proteins | 1 | 2022 | 85 | 0.210 |
Why?
|
| Disease Management | 3 | 2018 | 1052 | 0.210 |
Why?
|
| United States | 18 | 2018 | 15433 | 0.210 |
Why?
|
| United States Food and Drug Administration | 5 | 2018 | 332 | 0.210 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 221 | 0.210 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2020 | 86 | 0.210 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2021 | 612 | 0.210 |
Why?
|
| Herpesvirus 1, Human | 1 | 2022 | 113 | 0.210 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2019 | 160 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2022 | 447 | 0.200 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 1085 | 0.200 |
Why?
|
| Th2 Cells | 2 | 2005 | 257 | 0.200 |
Why?
|
| Eye Neoplasms | 1 | 2004 | 247 | 0.200 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 566 | 0.200 |
Why?
|
| HLA Antigens | 2 | 2012 | 546 | 0.200 |
Why?
|
| Head and Neck Neoplasms | 4 | 2020 | 3976 | 0.200 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 200 | 0.200 |
Why?
|
| Tanning | 1 | 2020 | 2 | 0.200 |
Why?
|
| Paclitaxel | 5 | 2015 | 1996 | 0.200 |
Why?
|
| Genes, p16 | 1 | 2021 | 125 | 0.200 |
Why?
|
| Vaccines, Synthetic | 2 | 2020 | 355 | 0.190 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2020 | 20 | 0.190 |
Why?
|
| Up-Regulation | 8 | 2020 | 2450 | 0.190 |
Why?
|
| Plasma | 2 | 2021 | 158 | 0.190 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2020 | 54 | 0.190 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2013 | 212 | 0.190 |
Why?
|
| History, 18th Century | 1 | 2020 | 89 | 0.190 |
Why?
|
| Spinal Neoplasms | 1 | 2006 | 631 | 0.190 |
Why?
|
| Public Health | 1 | 2023 | 299 | 0.190 |
Why?
|
| History, 19th Century | 1 | 2020 | 154 | 0.180 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2010 | 45 | 0.180 |
Why?
|
| Internationality | 3 | 2018 | 208 | 0.180 |
Why?
|
| Phenylbutyrates | 2 | 2017 | 59 | 0.180 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 149 | 0.180 |
Why?
|
| Cell-Derived Microparticles | 1 | 2020 | 41 | 0.180 |
Why?
|
| T-Lymphocytes | 5 | 2021 | 3869 | 0.180 |
Why?
|
| Self-Examination | 1 | 2019 | 12 | 0.180 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2012 | 155 | 0.180 |
Why?
|
| Kidney Neoplasms | 3 | 2009 | 3022 | 0.180 |
Why?
|
| GTP-Binding Protein alpha Subunits | 2 | 2018 | 34 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 524 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 5319 | 0.170 |
Why?
|
| Lymph Node Excision | 4 | 2020 | 1959 | 0.170 |
Why?
|
| Proteins | 3 | 2021 | 1963 | 0.170 |
Why?
|
| Steroid Hydroxylases | 1 | 2019 | 36 | 0.170 |
Why?
|
| Lung Neoplasms | 6 | 2023 | 11538 | 0.170 |
Why?
|
| RNA, Messenger | 5 | 2017 | 6150 | 0.170 |
Why?
|
| Proteome | 2 | 2021 | 561 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 216 | 0.170 |
Why?
|
| Administration, Oral | 3 | 2020 | 1544 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2020 | 185 | 0.170 |
Why?
|
| MART-1 Antigen | 3 | 2020 | 105 | 0.170 |
Why?
|
| Protein Engineering | 1 | 2019 | 100 | 0.170 |
Why?
|
| Dysplastic Nevus Syndrome | 2 | 2018 | 50 | 0.170 |
Why?
|
| History, 21st Century | 1 | 2020 | 441 | 0.160 |
Why?
|
| Chemoprevention | 1 | 2020 | 241 | 0.160 |
Why?
|
| Sulfoxides | 1 | 2018 | 22 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 529 | 0.160 |
Why?
|
| Capsules | 1 | 2018 | 53 | 0.160 |
Why?
|
| Multivariate Analysis | 4 | 2010 | 4298 | 0.160 |
Why?
|
| Child | 11 | 2024 | 29154 | 0.160 |
Why?
|
| Hospital Administrators | 1 | 2018 | 8 | 0.160 |
Why?
|
| Decision Making | 1 | 2006 | 1287 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 2359 | 0.160 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2019 | 170 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2020 | 574 | 0.160 |
Why?
|
| Central Tolerance | 1 | 2017 | 3 | 0.160 |
Why?
|
| Congresses as Topic | 2 | 2010 | 298 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 1350 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 4 | 2017 | 1290 | 0.160 |
Why?
|
| Research Design | 3 | 2018 | 1544 | 0.160 |
Why?
|
| Mitosis | 2 | 2013 | 615 | 0.160 |
Why?
|
| Virus Activation | 1 | 2019 | 228 | 0.150 |
Why?
|
| Information Dissemination | 1 | 2020 | 272 | 0.150 |
Why?
|
| Education, Nursing, Continuing | 1 | 2017 | 25 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2019 | 604 | 0.150 |
Why?
|
| Mice | 15 | 2020 | 34495 | 0.150 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2020 | 259 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 799 | 0.150 |
Why?
|
| Tuberculosis | 2 | 2019 | 548 | 0.150 |
Why?
|
| Incidence | 3 | 2020 | 5673 | 0.150 |
Why?
|
| Skin Ulcer | 2 | 2017 | 77 | 0.150 |
Why?
|
| RGS Proteins | 1 | 2017 | 61 | 0.150 |
Why?
|
| Research | 2 | 2011 | 415 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 4892 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 272 | 0.150 |
Why?
|
| Pyridines | 4 | 2018 | 1244 | 0.150 |
Why?
|
| Medical Records | 1 | 2018 | 415 | 0.150 |
Why?
|
| Phthalazines | 1 | 2019 | 253 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2017 | 479 | 0.150 |
Why?
|
| Dermatology | 1 | 2017 | 70 | 0.150 |
Why?
|
| Osteopontin | 1 | 2017 | 148 | 0.150 |
Why?
|
| Logistic Models | 2 | 2020 | 3441 | 0.150 |
Why?
|
| ErbB Receptors | 3 | 2017 | 2295 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 621 | 0.150 |
Why?
|
| Flow Cytometry | 5 | 2017 | 3033 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 1763 | 0.140 |
Why?
|
| Medical Oncology | 3 | 2021 | 1423 | 0.140 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 6009 | 0.140 |
Why?
|
| Tissue Distribution | 1 | 2018 | 875 | 0.140 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 860 | 0.140 |
Why?
|
| Mucous Membrane | 1 | 2017 | 271 | 0.140 |
Why?
|
| Cell Differentiation | 3 | 2020 | 4078 | 0.140 |
Why?
|
| Dermatitis | 1 | 2016 | 60 | 0.140 |
Why?
|
| Nevus of Ota | 1 | 2015 | 2 | 0.140 |
Why?
|
| DNA Methylation | 4 | 2017 | 2669 | 0.140 |
Why?
|
| Immune System | 2 | 2015 | 279 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 986 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 1742 | 0.140 |
Why?
|
| Antigen Presentation | 5 | 2019 | 272 | 0.140 |
Why?
|
| Aging | 1 | 2004 | 1582 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 3981 | 0.130 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2015 | 49 | 0.130 |
Why?
|
| RNA | 1 | 2020 | 1013 | 0.130 |
Why?
|
| Epitopes | 2 | 2012 | 685 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 3 | 2014 | 1165 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2019 | 426 | 0.130 |
Why?
|
| Models, Biological | 3 | 2014 | 3254 | 0.130 |
Why?
|
| Compassionate Use Trials | 1 | 2014 | 21 | 0.130 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 4 | 2022 | 59 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2018 | 279 | 0.130 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2012 | 88 | 0.130 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2017 | 383 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2015 | 9244 | 0.130 |
Why?
|
| Hearing Loss | 1 | 2016 | 153 | 0.130 |
Why?
|
| G(M2) Ganglioside | 1 | 2014 | 2 | 0.120 |
Why?
|
| Interleukin-10 | 2 | 2015 | 478 | 0.120 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2020 | 167 | 0.120 |
Why?
|
| Patient Rights | 1 | 2014 | 54 | 0.120 |
Why?
|
| Base Sequence | 5 | 2016 | 4917 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2023 | 2203 | 0.120 |
Why?
|
| Hemocyanins | 1 | 2014 | 50 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3821 | 0.120 |
Why?
|
| Melanoma, Experimental | 4 | 2020 | 368 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2016 | 315 | 0.120 |
Why?
|
| Monophenol Monooxygenase | 2 | 2012 | 59 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2016 | 382 | 0.120 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 132 | 0.120 |
Why?
|
| DNA Copy Number Variations | 2 | 2023 | 1516 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 1489 | 0.120 |
Why?
|
| Phenotype | 3 | 2014 | 6295 | 0.110 |
Why?
|
| Tetanus | 1 | 2013 | 25 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 134 | 0.110 |
Why?
|
| Mass Screening | 2 | 2022 | 1509 | 0.110 |
Why?
|
| Merkel cell polyomavirus | 1 | 2012 | 30 | 0.110 |
Why?
|
| Precancerous Conditions | 2 | 2014 | 1058 | 0.110 |
Why?
|
| Patient Safety | 2 | 2017 | 649 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 629 | 0.110 |
Why?
|
| Fatigue | 3 | 2020 | 1239 | 0.110 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 182 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 543 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2292 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 3154 | 0.110 |
Why?
|
| Lipids | 2 | 2013 | 644 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 674 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 244 | 0.110 |
Why?
|
| Histocompatibility Antigens | 1 | 2012 | 74 | 0.110 |
Why?
|
| Piperazines | 2 | 2019 | 2101 | 0.110 |
Why?
|
| Metastasectomy | 1 | 2014 | 200 | 0.110 |
Why?
|
| Polyomavirus Infections | 2 | 2012 | 139 | 0.110 |
Why?
|
| Thrombocytopenia | 2 | 2011 | 846 | 0.110 |
Why?
|
| Antigens, Surface | 2 | 2010 | 295 | 0.100 |
Why?
|
| DNA Primers | 2 | 2012 | 1399 | 0.100 |
Why?
|
| Alemtuzumab | 1 | 2012 | 198 | 0.100 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2011 | 44 | 0.100 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2012 | 69 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2011 | 78 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 70 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 503 | 0.100 |
Why?
|
| Diarrhea | 3 | 2023 | 686 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2011 | 87 | 0.100 |
Why?
|
| Vaccines, DNA | 1 | 2012 | 105 | 0.100 |
Why?
|
| Health | 1 | 2011 | 54 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 424 | 0.100 |
Why?
|
| Injections, Subcutaneous | 3 | 2007 | 334 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 105 | 0.100 |
Why?
|
| Immunization | 2 | 2010 | 397 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 1209 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 2315 | 0.100 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 69 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2017 | 787 | 0.100 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 178 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 441 | 0.100 |
Why?
|
| Blood Donors | 1 | 2011 | 164 | 0.100 |
Why?
|
| alpha-Fetoproteins | 1 | 2012 | 237 | 0.100 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2011 | 160 | 0.100 |
Why?
|
| Olea | 1 | 2010 | 1 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 46 | 0.100 |
Why?
|
| Genes, MHC Class II | 1 | 2010 | 67 | 0.100 |
Why?
|
| Fats | 1 | 2010 | 16 | 0.100 |
Why?
|
| Inflammation | 1 | 2021 | 2522 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 4 | 2010 | 3203 | 0.090 |
Why?
|
| Reference Standards | 1 | 2011 | 339 | 0.090 |
Why?
|
| Cetuximab | 1 | 2012 | 472 | 0.090 |
Why?
|
| Radiotherapy | 2 | 2016 | 1824 | 0.090 |
Why?
|
| World Health Organization | 1 | 2011 | 316 | 0.090 |
Why?
|
| Chemokines | 1 | 2011 | 314 | 0.090 |
Why?
|
| Naphthoquinones | 1 | 2009 | 18 | 0.090 |
Why?
|
| Tachycardia | 1 | 2010 | 70 | 0.090 |
Why?
|
| Drug Design | 1 | 2012 | 375 | 0.090 |
Why?
|
| Polyomavirus | 1 | 2009 | 30 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 1399 | 0.090 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 74 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 2283 | 0.090 |
Why?
|
| Recurrence | 2 | 2010 | 4758 | 0.090 |
Why?
|
| Interleukin-12 | 2 | 2011 | 253 | 0.090 |
Why?
|
| Iceland | 1 | 2009 | 12 | 0.090 |
Why?
|
| Obesity | 2 | 2023 | 2884 | 0.090 |
Why?
|
| Trastuzumab | 1 | 2012 | 696 | 0.090 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2009 | 110 | 0.090 |
Why?
|
| Amino Acid Sequence | 7 | 2012 | 4233 | 0.090 |
Why?
|
| Lymphoid Tissue | 1 | 2009 | 95 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 1866 | 0.090 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2008 | 13 | 0.090 |
Why?
|
| Gene Expression | 2 | 2017 | 3570 | 0.090 |
Why?
|
| Forecasting | 2 | 2011 | 694 | 0.080 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 716 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2009 | 187 | 0.080 |
Why?
|
| Vinblastine | 3 | 2017 | 453 | 0.080 |
Why?
|
| Cattle | 1 | 2010 | 783 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 761 | 0.080 |
Why?
|
| Pregnancy | 2 | 2020 | 7573 | 0.080 |
Why?
|
| Genome | 1 | 2012 | 672 | 0.080 |
Why?
|
| Fibronectins | 1 | 2009 | 197 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 709 | 0.080 |
Why?
|
| Immunotherapy, Active | 1 | 2008 | 46 | 0.080 |
Why?
|
| Bevacizumab | 1 | 2012 | 938 | 0.080 |
Why?
|
| Italy | 3 | 2014 | 236 | 0.080 |
Why?
|
| Molecular Sequence Data | 7 | 2011 | 6089 | 0.080 |
Why?
|
| Mycoplasma penetrans | 1 | 2007 | 1 | 0.080 |
Why?
|
| Body Weight | 2 | 2011 | 1293 | 0.080 |
Why?
|
| Liver Neoplasms | 2 | 2004 | 4557 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2015 | 5637 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 32 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 666 | 0.080 |
Why?
|
| Down-Regulation | 3 | 2018 | 2074 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 3639 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 1163 | 0.080 |
Why?
|
| Endostatins | 1 | 2007 | 48 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2017 | 769 | 0.080 |
Why?
|
| Biological Therapy | 1 | 2007 | 58 | 0.080 |
Why?
|
| Sample Size | 1 | 2008 | 202 | 0.080 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2018 | 52 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 172 | 0.070 |
Why?
|
| Oxides | 1 | 2008 | 211 | 0.070 |
Why?
|
| Nausea | 2 | 2023 | 525 | 0.070 |
Why?
|
| Arsenicals | 1 | 2008 | 201 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2017 | 3518 | 0.070 |
Why?
|
| Dimerization | 1 | 2007 | 304 | 0.070 |
Why?
|
| Risk | 2 | 2010 | 1972 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 2 | 2017 | 2518 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 840 | 0.070 |
Why?
|
| Pruritus | 2 | 2020 | 87 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2012 | 1694 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 534 | 0.070 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2006 | 10 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 6942 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2007 | 237 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2008 | 311 | 0.070 |
Why?
|
| Hypopigmentation | 1 | 2006 | 28 | 0.070 |
Why?
|
| Proteomics | 2 | 2014 | 1380 | 0.070 |
Why?
|
| MicroRNAs | 2 | 2010 | 2947 | 0.070 |
Why?
|
| Nitrosourea Compounds | 1 | 2005 | 12 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2011 | 1234 | 0.070 |
Why?
|
| Models, Statistical | 2 | 2012 | 1171 | 0.070 |
Why?
|
| Benchmarking | 1 | 2008 | 273 | 0.070 |
Why?
|
| Methionine | 1 | 2006 | 159 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2009 | 1391 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2005 | 101 | 0.070 |
Why?
|
| Proteasome Inhibitors | 1 | 2006 | 231 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 299 | 0.070 |
Why?
|
| Mitochondria | 1 | 2012 | 1282 | 0.070 |
Why?
|
| HLA-DP Antigens | 1 | 2005 | 21 | 0.070 |
Why?
|
| Stereotaxic Techniques | 1 | 2006 | 172 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2005 | 129 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 582 | 0.060 |
Why?
|
| Interleukins | 2 | 2007 | 325 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2007 | 1008 | 0.060 |
Why?
|
| Placebos | 2 | 2019 | 437 | 0.060 |
Why?
|
| RNA, Neoplasm | 2 | 2004 | 771 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2004 | 171 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2004 | 425 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2007 | 1258 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 554 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 2086 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2007 | 1493 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2006 | 255 | 0.060 |
Why?
|
| Age Factors | 3 | 2019 | 5377 | 0.060 |
Why?
|
| Cell Movement | 2 | 2011 | 2466 | 0.060 |
Why?
|
| Amifostine | 1 | 2003 | 97 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 945 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2015 | 130 | 0.060 |
Why?
|
| HLA-A Antigens | 1 | 2023 | 102 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 669 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 675 | 0.060 |
Why?
|
| Glycolysis | 2 | 2019 | 519 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2004 | 242 | 0.060 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 677 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4638 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 1064 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 575 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 77 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2002 | 43 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2004 | 756 | 0.050 |
Why?
|
| Protein Binding | 4 | 2014 | 3438 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2002 | 63 | 0.050 |
Why?
|
| Receptors, Interferon | 2 | 2017 | 44 | 0.050 |
Why?
|
| Ligands | 2 | 2014 | 995 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 2576 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 1029 | 0.050 |
Why?
|
| Algorithms | 2 | 2011 | 3890 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2307 | 0.050 |
Why?
|
| Contactin 1 | 1 | 2021 | 5 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2006 | 1014 | 0.050 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2021 | 38 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2019 | 1681 | 0.050 |
Why?
|
| Genotype | 3 | 2014 | 4109 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2007 | 1048 | 0.050 |
Why?
|
| ADAM10 Protein | 1 | 2020 | 12 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 4744 | 0.050 |
Why?
|
| Lymphoma | 1 | 2009 | 1467 | 0.050 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2020 | 75 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2015 | 1146 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 5687 | 0.050 |
Why?
|
| Transaminases | 1 | 2020 | 76 | 0.050 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2020 | 96 | 0.050 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 117 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2002 | 842 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2054 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2020 | 157 | 0.040 |
Why?
|
| Tumor Virus Infections | 2 | 2012 | 224 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2019 | 1129 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 1823 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 1217 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 2508 | 0.040 |
Why?
|
| Oxysterols | 1 | 2019 | 3 | 0.040 |
Why?
|
| Reserpine | 1 | 2019 | 10 | 0.040 |
Why?
|
| Telomere | 1 | 2022 | 505 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 748 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 1162 | 0.040 |
Why?
|
| Keratin-20 | 2 | 2012 | 44 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2021 | 269 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2014 | 289 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2017 | 1335 | 0.040 |
Why?
|
| Exanthema | 1 | 2021 | 211 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2019 | 61 | 0.040 |
Why?
|
| Benzenesulfonates | 2 | 2012 | 195 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 55 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2019 | 159 | 0.040 |
Why?
|
| CD56 Antigen | 1 | 2019 | 83 | 0.040 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 62 | 0.040 |
Why?
|
| Oleic Acids | 2 | 2008 | 13 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 2 | 2009 | 91 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 760 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2022 | 1549 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2019 | 102 | 0.040 |
Why?
|
| Antibodies | 2 | 2015 | 838 | 0.040 |
Why?
|
| Mannitol | 2 | 2008 | 54 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2021 | 519 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2022 | 1070 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 702 | 0.040 |
Why?
|
| Neutropenia | 1 | 2003 | 968 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2019 | 348 | 0.040 |
Why?
|
| Salvage Therapy | 2 | 2020 | 2054 | 0.040 |
Why?
|
| Receptor, ErbB-4 | 1 | 2017 | 23 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 460 | 0.040 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2017 | 46 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 222 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2011 | 626 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 276 | 0.040 |
Why?
|
| Beclin-1 | 1 | 2017 | 85 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 255 | 0.040 |
Why?
|
| Comorbidity | 1 | 2004 | 2352 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 106 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 284 | 0.040 |
Why?
|
| Neuropilin-1 | 1 | 2017 | 40 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 550 | 0.040 |
Why?
|
| Herpesviridae | 1 | 2017 | 42 | 0.040 |
Why?
|
| Ulcer | 1 | 2017 | 78 | 0.040 |
Why?
|
| Histone Deacetylase 6 | 1 | 2017 | 44 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2013 | 16273 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2017 | 92 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2017 | 3536 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 100 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2017 | 263 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2003 | 1555 | 0.030 |
Why?
|
| Hypoxia | 1 | 2019 | 443 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 74 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.030 |
Why?
|
| Myeloproliferative Disorders | 1 | 2003 | 767 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2016 | 170 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2020 | 874 | 0.030 |
Why?
|
| Melanins | 1 | 2015 | 50 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2009 | 1382 | 0.030 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Surgical Oncology | 1 | 2017 | 190 | 0.030 |
Why?
|
| Indazoles | 1 | 2017 | 297 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 733 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2017 | 365 | 0.030 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2014 | 45 | 0.030 |
Why?
|
| Clone Cells | 2 | 2006 | 555 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 266 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 4320 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 573 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2014 | 162 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 149 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2013 | 107 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 2488 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 15694 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 233 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2020 | 1682 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 182 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 2139 | 0.030 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2012 | 47 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 2012 | 47 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 194 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1559 | 0.030 |
Why?
|
| Glucose | 1 | 2019 | 1248 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2012 | 52 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 235 | 0.030 |
Why?
|
| Morpholines | 1 | 2014 | 289 | 0.030 |
Why?
|
| Virus Integration | 1 | 2012 | 76 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 4143 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 1408 | 0.030 |
Why?
|
| Binding Sites | 2 | 2009 | 2171 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 927 | 0.030 |
Why?
|
| Genes, ras | 1 | 2015 | 667 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2013 | 2218 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 419 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2738 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 1390 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2011 | 91 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 1363 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 1489 | 0.030 |
Why?
|
| Chemokine CCL21 | 1 | 2011 | 4 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 856 | 0.030 |
Why?
|
| Poly I-C | 1 | 2011 | 29 | 0.020 |
Why?
|
| Transfection | 2 | 2009 | 2944 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 1294 | 0.020 |
Why?
|
| Alleles | 2 | 2009 | 2437 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 1037 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 837 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2012 | 253 | 0.020 |
Why?
|
| Hydrazines | 1 | 2012 | 208 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 256 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 3045 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 111 | 0.020 |
Why?
|
| COS Cells | 1 | 2010 | 377 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 1082 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2010 | 175 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 905 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2010 | 170 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 369 | 0.020 |
Why?
|
| Pyrroles | 1 | 2014 | 576 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2011 | 208 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2014 | 1665 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2008 | 5395 | 0.020 |
Why?
|
| Australia | 1 | 2010 | 225 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 668 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 4821 | 0.020 |
Why?
|
| Colitis | 1 | 2013 | 340 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2017 | 4307 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 231 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 1519 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 259 | 0.020 |
Why?
|
| Cell Line | 2 | 2007 | 5114 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5710 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2014 | 1152 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 3151 | 0.020 |
Why?
|
| Japan | 1 | 2009 | 227 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2010 | 447 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 202 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2009 | 211 | 0.020 |
Why?
|
| Vitiligo | 1 | 2008 | 14 | 0.020 |
Why?
|
| Piperidines | 1 | 2014 | 1035 | 0.020 |
Why?
|
| Education | 1 | 2008 | 112 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 419 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 649 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 1869 | 0.020 |
Why?
|
| Craniotomy | 1 | 2010 | 304 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 612 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2007 | 92 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 1678 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 2216 | 0.020 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2008 | 76 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 997 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 886 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2009 | 486 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 700 | 0.020 |
Why?
|
| Sirolimus | 1 | 2012 | 814 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1053 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2007 | 64 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 1323 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2009 | 694 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 1062 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8223 | 0.020 |
Why?
|
| Software | 1 | 2014 | 1321 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 475 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 829 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 383 | 0.020 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 82 | 0.020 |
Why?
|
| Health Education | 1 | 2008 | 309 | 0.020 |
Why?
|
| HLA-DP beta-Chains | 1 | 2005 | 15 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 4971 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 1538 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 1130 | 0.020 |
Why?
|
| Vincristine | 1 | 2008 | 1511 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 558 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2004 | 173 | 0.020 |
Why?
|
| Centrifugation | 1 | 2004 | 66 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 2004 | 81 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2004 | 88 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 866 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 371 | 0.010 |
Why?
|
| Axilla | 1 | 2006 | 902 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 259 | 0.010 |
Why?
|
| Enzymes | 1 | 2004 | 64 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 207 | 0.010 |
Why?
|
| HLA-DRB1 Chains | 1 | 2003 | 82 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 2483 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2017 | 5270 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2003 | 128 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 1073 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2003 | 250 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2003 | 48 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 4804 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2008 | 2316 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2002 | 26 | 0.010 |
Why?
|
| Reoperation | 1 | 2007 | 1382 | 0.010 |
Why?
|
| Hypotension | 1 | 2003 | 210 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 2086 | 0.010 |
Why?
|
| Histamine | 1 | 2002 | 53 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 2370 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 7789 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2008 | 732 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 3001 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2008 | 862 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1618 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 639 | 0.010 |
Why?
|
| Survivors | 1 | 2005 | 1031 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2005 | 977 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2003 | 679 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1819 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1467 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 1459 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 915 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 1756 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 2004 | 3168 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 7702 | 0.010 |
Why?
|